Brian Hubbard

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

Ampersand Management LLC (Ampersand Management) is a private equity firm founded in 1988 by Richard A. Charpie. The firm is headquartered in Wellesley, Massachusetts.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York.

Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver.

Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd

Topivert Pharma Ltd. is a British pharmaceutical company founded in 2011. The private company develops non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal.

Lundbeckfonden Emerge (Emerge) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2012 and is headquartered in Copenhagen, Denmark.

Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada.

Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA.

Jecure Therapeutics, Inc. provides therapeutic services for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company was founded by Ariel Feldstein in 2015 and is headquartered in San Diego, CA.

Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom.

Magnolia Neurosciences Corp. operates as a drug discovery and development company. The firm focuses on the creation of a novel class of neuroprotective medicines. The company was founded in 2018 and is headquartered in Seattle, WA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022.

Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA.

Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware.

Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom.

Entrepreneurship Lab NYC is an entrepreneurship education and networking program that was founded in 2012. The program focuses on first-time founders with prior entrepreneurship education and is centered around bio and health tech. The goal of the program is to provide these founders with the basic skills and knowledge they need to succeed in their entrepreneurial endeavors.

Trex Bio, Inc. manufactures immunotherapies for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, CA.

Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA.